Thalidomide in the treatment of Kaposi's sarcoma

Dermatology

Volumn 215, Issue 3, 2007, Pages 240-244

  Rubegni, Pietro ^a,b   Sbano, Paolo ^a   De Aloe, Giovambattista ^a   Flori, Maria Laura ^a   Fimiani, Michele ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

Kaposi's sarcoma; Thalidomide

Indexed keywords

THALIDOMIDE;

ADULT; AIDS RELATED COMPLEX; ARTICLE; CANCER REGRESSION; CASE REPORT; DRUG DOSE REDUCTION; DRUG EFFICACY; ELECTROMYOGRAM; FEMALE; HUMAN; HUMAN HERPESVIRUS 8; KAPOSI SARCOMA; MALE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SIDE EFFECT; SKIN MANIFESTATION; TREATMENT DURATION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; HUMANS; SARCOMA, KAPOSI; THALIDOMIDE;

EID: 34548477395     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000106583     Document Type: Article

References (22)

1. Sanders C, Canninga-van Dijk M, Borleffs J: Kaposi's sarcoma. Lancet 2004;364:1549-1552.
2. Buonaguro FM, Tornesello ML, Buonaguro L, Satriano RA, Ruocco E, Castello G, Ruocco V: Kaposi's sarcoma: aetiopathogenesis, histology and clinical features. J Eur Acad Dermatol Venereol 2003;17:138-154.
3. Viejo-Borbolla A, Schultz TF: Kaposi's sarcoma-associated herpesvirus (KSHV/HHV8): key aspects of epidemiology and pathogenesis. AIDS Rev 2003;5:222-229.
4. Cattelan AM, Trevenzoli M, Aversa SM: Recent advances in the treatment of AIDS-related Kaposi's sarcoma. Am J Clin Dermatol 2002;3:451-462.
5. Mendez JC, Procop GW, Espy MJ, Paya CV, Smith TF: Detection and semiquantitative analysis of human herpesvirus 8 DNA in specimens from patients with Kaposi's sarcoma. J Clin Microbiol 1998;36:2220-2222.
6. Kazakov DV, Schmid M, Adams V, Cathomas G, Muller B, Burg G, Kempf W: HHV-8 DNA sequences in the peripheral blood and skin lesions of an HIV-negative patient with multiple eruptive dermatofibromas: implications for the detection of HHV-8 as a diagnostic marker for Kaposi's sarcoma. Dermatology 2003;206:217-221.
7. Brambilla L, Labianca R, Ferrucci SM, Taglioni M, Boneschi V: Treatment of classical Kaposi's sarcoma with gemcitabine. Dermatology 2001;202:119-122.
8. Krown SE: Management of Kaposi sarcoma: the role of interferon and thalidomide. Curr Opin Oncol 2001;13:374-381.
9. Soler RA, Howard M, Brink NS, Gibb D, Tedder RS, Nadal D: Regression of AIDS-related Kaposi's sarcoma during therapy with thalidomide. Clin Infect Dis 1996;23:501-503.
10. Krown SE: Therapy of AIDS-associated Kaposi's sarcoma: targeting pathogenetic mechanism. Hematol Oncol Clin North Am 2003;17:763-783.
11. Okafor MC: Thalidomide for erythema nodosum leprosum and other applications. Pharmacotherapy 2003;23:481-493.
12. Wu JJ, Huang DB, Pang KR, Hsu S, Tyring SK: Thalidomide: dermatological indications, mechanisms of action and side-effects. Br J Dermatol 2005;153:254-273.
13. Jacob SE, Fien S, Kerdel FA: Scleromyxedema, a positive effect with thalidomide. Dermatology 2006;213:150-152.
14. Sander CS, Kaatz M, Elsner P: Successful treatment of cutaneous Langerhans cell histiocytosis with thalidomide. Dermatology 2004;208:149-152.
15. Fife K, Howard MR, Gracie F, Phillips RH, Bower M: Activity of thalidomide in AIDSrelated Kaposi's sarcoma and correlation with HHV-8 titre. Int J STD AIDS 1998;9:751-755.
16. Little RF, Wyvill KM, Pluda JM, Welles L, Marshall V, Figg WD, Newcomb FM, Tosato G, Feigal E, Steinberg SM, Whitby D, Goedert JJ, Yarchoan R: Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 2000;18:2593-2602.
17. D'Amato RJ, Loughnan MS, Flynn E, Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082-4085.
18. Lepper ER, Ng SS, Gutschow M, Weiss M, Hauschildt S, Hecker TK, Luzzio FA, Eger K, Figg WD: Comparative molecular field analysis and comparative molecular similarity indices analysis of thalidomide analogues as angiogenesis inhibitors. J Med Chem 2004;47:2219-2227.
19. de Medeiros BC, Rezuke WN, Ricci A Jr, Tsongalis G, Shen PU, Bona RD, Feingold JM, Edwards RL, Tutschka PJ, Bilgrami S: Kaposi's sarcoma following allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia. Acta Haematol 2000;104:115-118.
20. González-López MA, Rodrigo E, González-Vela MC, Fernández-Llaca H, Arias-Rodríguez MA, Val-Bernal JF: Posttransplant Kaposi's sarcoma restricted to the site of a previous deep venous thrombosis: abrupt onset after withdrawal of sirolimus. Dermatology 2006;213:30-33.
21. Milazzo L, Biasin M, Gatti N, Piacentini L, Niero F, Zanone Poma B, Galli M, Moroni M, Clerici M, Riva A: Thalidomide in the treatment of chronic hepatitis C unresponsive to α-interferon and ribavirin. Am J Gastroenterol 2006;101:399-402.
22. Briani C, Zara G, Rondinone R, Della Libera S, Ermani M, Ruggero S, Ghirardello A, Zampieri S, Doria A: Thalidomide neurotoxicity: prospective study in patients with lupus erythematosus. Neurology 2004;62:2288-2290.